CN104768949A - 苯并呋咱抗淀粉样蛋白化合物和方法 - Google Patents

苯并呋咱抗淀粉样蛋白化合物和方法 Download PDF

Info

Publication number
CN104768949A
CN104768949A CN201380055866.6A CN201380055866A CN104768949A CN 104768949 A CN104768949 A CN 104768949A CN 201380055866 A CN201380055866 A CN 201380055866A CN 104768949 A CN104768949 A CN 104768949A
Authority
CN
China
Prior art keywords
mmol
base
etoac
added
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380055866.6A
Other languages
English (en)
Chinese (zh)
Inventor
马克·A·里德
托马斯·K·伍德
斯科特·C·班菲尔德
克里斯多佛·J·巴登
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Treventis Corp
Original Assignee
Treventis Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Treventis Corp filed Critical Treventis Corp
Publication of CN104768949A publication Critical patent/CN104768949A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • E—FIXED CONSTRUCTIONS
    • E21—EARTH OR ROCK DRILLING; MINING
    • E21B—EARTH OR ROCK DRILLING; OBTAINING OIL, GAS, WATER, SOLUBLE OR MELTABLE MATERIALS OR A SLURRY OF MINERALS FROM WELLS
    • E21B36/00—Heating, cooling or insulating arrangements for boreholes or wells, e.g. for use in permafrost zones
    • E21B36/001—Cooling arrangements
    • E—FIXED CONSTRUCTIONS
    • E21—EARTH OR ROCK DRILLING; MINING
    • E21B—EARTH OR ROCK DRILLING; OBTAINING OIL, GAS, WATER, SOLUBLE OR MELTABLE MATERIALS OR A SLURRY OF MINERALS FROM WELLS
    • E21B36/00—Heating, cooling or insulating arrangements for boreholes or wells, e.g. for use in permafrost zones
    • E21B36/003—Insulating arrangements
    • E—FIXED CONSTRUCTIONS
    • E21—EARTH OR ROCK DRILLING; MINING
    • E21B—EARTH OR ROCK DRILLING; OBTAINING OIL, GAS, WATER, SOLUBLE OR MELTABLE MATERIALS OR A SLURRY OF MINERALS FROM WELLS
    • E21B36/00—Heating, cooling or insulating arrangements for boreholes or wells, e.g. for use in permafrost zones
    • E21B36/04—Heating, cooling or insulating arrangements for boreholes or wells, e.g. for use in permafrost zones using electrical heaters
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
    • F16L—PIPES; JOINTS OR FITTINGS FOR PIPES; SUPPORTS FOR PIPES, CABLES OR PROTECTIVE TUBING; MEANS FOR THERMAL INSULATION IN GENERAL
    • F16L11/00—Hoses, i.e. flexible pipes
    • F16L11/20—Double-walled hoses
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
    • F16L—PIPES; JOINTS OR FITTINGS FOR PIPES; SUPPORTS FOR PIPES, CABLES OR PROTECTIVE TUBING; MEANS FOR THERMAL INSULATION IN GENERAL
    • F16L53/00—Heating of pipes or pipe systems; Cooling of pipes or pipe systems
    • F16L53/30—Heating of pipes or pipe systems
    • F16L53/35—Ohmic-resistance heating
    • F16L53/38—Ohmic-resistance heating using elongate electric heating elements, e.g. wires or ribbons
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
    • F16L—PIPES; JOINTS OR FITTINGS FOR PIPES; SUPPORTS FOR PIPES, CABLES OR PROTECTIVE TUBING; MEANS FOR THERMAL INSULATION IN GENERAL
    • F16L9/00—Rigid pipes
    • F16L9/18—Double-walled pipes; Multi-channel pipes or pipe assemblies
    • F16L9/19—Multi-channel pipes or pipe assemblies
    • F16L9/20—Pipe assemblies
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02G—INSTALLATION OF ELECTRIC CABLES OR LINES, OR OF COMBINED OPTICAL AND ELECTRIC CABLES OR LINES
    • H02G3/00—Installations of electric cables or lines or protective tubing therefor in or on buildings, equivalent structures or vehicles
    • H02G3/36—Installations of cables or lines in walls, floors or ceilings
    • H02G3/38—Installations of cables or lines in walls, floors or ceilings the cables or lines being installed in preestablished conduits or ducts

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Geology (AREA)
  • Mining & Mineral Resources (AREA)
  • General Engineering & Computer Science (AREA)
  • Fluid Mechanics (AREA)
  • Geochemistry & Mineralogy (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Environmental & Geological Engineering (AREA)
  • Physics & Mathematics (AREA)
  • Mechanical Engineering (AREA)
  • Health & Medical Sciences (AREA)
  • Architecture (AREA)
  • Civil Engineering (AREA)
  • Structural Engineering (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Laying Of Electric Cables Or Lines Outside (AREA)
CN201380055866.6A 2012-08-24 2013-08-22 苯并呋咱抗淀粉样蛋白化合物和方法 Pending CN104768949A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261693011P 2012-08-24 2012-08-24
US61/693,011 2012-08-24
PCT/US2013/056220 WO2014031873A2 (en) 2012-08-24 2013-08-22 Benzofurazan anti-amyloid compounds and methods

Publications (1)

Publication Number Publication Date
CN104768949A true CN104768949A (zh) 2015-07-08

Family

ID=50150397

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380055866.6A Pending CN104768949A (zh) 2012-08-24 2013-08-22 苯并呋咱抗淀粉样蛋白化合物和方法

Country Status (14)

Country Link
US (2) US9328078B2 (https=)
EP (1) EP2888252B1 (https=)
JP (1) JP6219955B2 (https=)
KR (1) KR102046499B1 (https=)
CN (1) CN104768949A (https=)
AU (1) AU2013305663B2 (https=)
BR (1) BR112015003824B1 (https=)
CA (1) CA2883221C (https=)
IL (1) IL237305B (https=)
MX (1) MX365851B (https=)
NZ (1) NZ705167A (https=)
RU (1) RU2641293C2 (https=)
WO (2) WO2014031873A2 (https=)
ZA (1) ZA201501161B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6663361B2 (ja) * 2014-02-27 2020-03-11 トレヴェンティス コーポレーション ベンゾフラザンを含有する抗アミロイド化合物
DE102014214687A1 (de) * 2014-07-25 2016-01-28 Contitech Techno-Chemie Gmbh Beheizbarer Schlauch
EP3634950B1 (en) * 2017-06-06 2022-03-09 Council of Scientific and Industrial Research Cobalt complexes, process for preparation and use thereof
CN108566693B (zh) * 2017-11-27 2020-12-25 安邦电气股份有限公司 一种高效率伴热带
CN108235475B (zh) * 2017-11-27 2021-01-22 安邦电气股份有限公司 一种便于使用的伴热带
US20230365516A1 (en) * 2020-07-14 2023-11-16 Washington University Compounds for cancer therapy and imaging

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005058915A1 (en) * 2003-12-12 2005-06-30 Glaxo Group Limited Tricyclic indole hydroxyethylamine derivatives and their use in the treatment of alzheimer's disease
CN1735592A (zh) * 2002-12-05 2006-02-15 葛兰素集团有限公司 用于阿耳茨海默氏病的羟基乙基胺衍生物
CN102170882A (zh) * 2008-08-29 2011-08-31 特温蒂斯公司 治疗淀粉状蛋白疾病的组合物和方法
WO2012080727A2 (en) * 2010-12-14 2012-06-21 Electrophoretics Limited Casein kinase 1delta (ck1delta) inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3971416A (en) * 1974-08-16 1976-07-27 Thermon Manufacturing Company Preinsulated pipe assembly and pipeline
DE19643037A1 (de) * 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
JP2002228081A (ja) * 2001-02-06 2002-08-14 Nitta Moore Co 保温・移送用配管
PL369674A1 (en) * 2001-11-14 2005-05-02 Merck Patent Gmbh Pyrazole derivatives as psychopharmaceuticals
JP2003328402A (ja) * 2002-05-16 2003-11-19 Sekisui Chem Co Ltd ヒータ挿入ガイド付き管
JP2004244958A (ja) * 2003-02-14 2004-09-02 Sekisui Chem Co Ltd 凍結防止用流水配管
WO2006002284A1 (en) * 2004-06-22 2006-01-05 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
GB2423811A (en) * 2005-03-02 2006-09-06 Valpar Ind Ltd Improved Beverage Python

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1735592A (zh) * 2002-12-05 2006-02-15 葛兰素集团有限公司 用于阿耳茨海默氏病的羟基乙基胺衍生物
WO2005058915A1 (en) * 2003-12-12 2005-06-30 Glaxo Group Limited Tricyclic indole hydroxyethylamine derivatives and their use in the treatment of alzheimer's disease
CN102170882A (zh) * 2008-08-29 2011-08-31 特温蒂斯公司 治疗淀粉状蛋白疾病的组合物和方法
WO2012080727A2 (en) * 2010-12-14 2012-06-21 Electrophoretics Limited Casein kinase 1delta (ck1delta) inhibitors

Also Published As

Publication number Publication date
CA2883221C (en) 2020-01-21
WO2014031873A2 (en) 2014-02-27
KR20150046263A (ko) 2015-04-29
IL237305A0 (en) 2015-04-30
US20150266838A1 (en) 2015-09-24
BR112015003824A2 (pt) 2018-05-29
EP2888252B1 (en) 2017-06-07
US20160264535A1 (en) 2016-09-15
EP2888252A2 (en) 2015-07-01
IL237305B (en) 2018-08-30
BR112015003824B1 (pt) 2022-10-04
EP2888252A4 (en) 2016-01-06
NZ705167A (en) 2017-12-22
AU2013305663B2 (en) 2017-11-02
JP2015526475A (ja) 2015-09-10
WO2014031942A1 (en) 2014-02-27
US9328078B2 (en) 2016-05-03
ZA201501161B (en) 2016-06-29
KR102046499B1 (ko) 2019-11-19
MX2015002418A (es) 2015-09-21
AU2013305663A1 (en) 2015-03-05
MX365851B (es) 2019-06-17
CA2883221A1 (en) 2014-02-27
RU2015110256A (ru) 2016-10-10
WO2014031873A3 (en) 2014-04-17
JP6219955B2 (ja) 2017-10-25
RU2641293C2 (ru) 2018-01-17

Similar Documents

Publication Publication Date Title
TWI287449B (en) Gyrase inhibitors and uses thereof
CN108299425B (zh) 稠环衍生物、其制备方法、中间体、药物组合物及应用
CN104768949A (zh) 苯并呋咱抗淀粉样蛋白化合物和方法
EA018412B1 (ru) Производные изоксазола и их применение в качестве потенциирующих средств для метаботропных глутаматных рецепторов
CN112409363A (zh) 用于治疗认知损害的苯并二氮杂䓬衍生物、组合物和方法
CN108026050A (zh) 作为RORγ调节剂的新型化合物
AU2005294404A1 (en) Compounds for Alzheimer's disease
CN107827841A (zh) 作为Rorγt调节剂的三氟甲基醇
CN105308037B (zh) 三唑化合物及其作为γ分泌酶调节剂的用途
CN107108598A (zh) 作为Rorγt调节剂的噻唑
CN112292183A (zh) 作为RORγt的调节剂的6-氨基吡啶-3-基吡唑
CN107922391A (zh) 吡啶和嘧啶衍生物
CN101137655A (zh) 雄激素受体调节剂化合物和方法
CN114008040B (zh) 用于调节fxr的化合物
CN115304590A (zh) 2h-苯并三氮唑衍生物及其制备方法及含有它们的药物组合物
CN107074844A (zh) 吡唑衍生物的制造方法
JP6401254B2 (ja) プロキネシチン受容体のモジュレータとしての１−スルホニルピペリジン誘導体
JP7696354B2 (ja) 睡眠障害の治療のためのＨ１および５－ＨＴ２Ａ受容体調節物質としての３－（４－（１１Ｈ－ジベンゾ［ｂ，ｅ］［１，４］アゼピン－６－イル）ピペラジン－１－イル）－プロパン酸誘導体および３－（４－（ジベンゾ［ｂ，ｆ］［１，４］オキサゼピン／チアゼピン／ジアゼピン－１１－イル）ピペラジン－１－イル）－プロパン酸誘導体
JP6663361B2 (ja) ベンゾフラザンを含有する抗アミロイド化合物
HK40046882A (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK40093069A (zh) 吡啶并[4，3-b]吲哚衍生物及其作为药物的用途
HK1240210B (zh) 酰胺类衍生物、其制备方法及其在医药上的用途
CN106674207A (zh) 取代的芳基杂芳基化合物及其用途
HK1254362B (zh) 用於治疗认知损害的苯并二氮杂环庚三烯衍生物、组合物和方法
HK1237335B (zh) 咪唑并哒嗪化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150708

WD01 Invention patent application deemed withdrawn after publication